高级检索
高雅楠, 陈雷, 刘胜, 储凯. 脊髓灰质炎灭活疫苗免疫效果中母传抗体作用[J]. 中国公共卫生, 2020, 36(10): 1459-1462. DOI: 10.11847/zgggws1123377
引用本文: 高雅楠, 陈雷, 刘胜, 储凯. 脊髓灰质炎灭活疫苗免疫效果中母传抗体作用[J]. 中国公共卫生, 2020, 36(10): 1459-1462. DOI: 10.11847/zgggws1123377
GAO Ya-nan, CHEN Lei, LIU Sheng, . Effect of maternal antibodies on immune response of Sabin inactivated poliovirus vaccine among two-month old infants in China[J]. Chinese Journal of Public Health, 2020, 36(10): 1459-1462. DOI: 10.11847/zgggws1123377
Citation: GAO Ya-nan, CHEN Lei, LIU Sheng, . Effect of maternal antibodies on immune response of Sabin inactivated poliovirus vaccine among two-month old infants in China[J]. Chinese Journal of Public Health, 2020, 36(10): 1459-1462. DOI: 10.11847/zgggws1123377

脊髓灰质炎灭活疫苗免疫效果中母传抗体作用

Effect of maternal antibodies on immune response of Sabin inactivated poliovirus vaccine among two-month old infants in China

  • 摘要:
      目的  分析母传抗体对婴儿不同疫苗剂量免疫效果的影响。
      方法  2016 — 2017年在江苏省邳州市招募2月龄(60~90 d)婴儿360名,以分别接受3剂次低、中、高剂量Sabin株脊髓灰质炎试验疫苗接种且有免疫前、免疫后1个月有效血清结果的受试者作为研究对象,分析免疫效果及其影响因素。
      结果  342名研究对象纳入分析,低、中、高剂量组I、II、III型抗体阳性率均高达99.13 % 以上。免疫前抗体滴度 < 1 ∶ 8时,免疫后几何平均增长倍数(GMI)低、中、高剂量组分别为Ⅰ型:1 289.14、1 312.49、2 430.83,Ⅱ型:51.86、101.35、141.04,Ⅲ型:338.25、540.45、760.52;滴度1 ∶ 8~< 32时,GMI分别为Ⅰ型:209.54、458.39、454.71,Ⅱ型:7.89、18.10、34.81,Ⅲ型:116.88、260.05、192.83;滴度 > 1 ∶ 32时,GMI分别为Ⅰ型:25.35、34.16、90.48,Ⅱ型:1.05、6.17、4.26,Ⅲ型:11.39、20.97、42.22。
      结论  该疫苗可以产生良好的免疫原性效果,母传抗体在一定程度上能够降低疫苗免疫效果。

     

    Abstract:
      Objective  To analyze the influence of maternal anti-poliovirus antibodies on the immune response of different dose Sabin inactivated poliovirus vaccine (sIPV) among infants.
      Methods  We recruited 360 two-month (60 – 90 days) old infants in Pizhou city of Jiangsu province during 2016 – 2017 and vaccinated the infants with three doses of sIPV. Two milliliters venous blood were sampled from each of the infants one month before and after the vaccination for the detection of type I, II and III neutralizing antibodies to poliovirus with neutralization test. The effectiveness and influence factors of the immune response of sIPV were evaluated.
      Results  For the 342 infants with valid information, the mean seropositive rate of type I, II and III antibody were all equal to or above 99.13% among the infants with low/moderate/high dose sIPV vaccination. For the infants with the low/moderate/high dose sIPV vaccination and with the antibody titer of less than 1 : 8 before the vaccination, the geometric mean increases (GMIs) were 1 289.14/1 312.49/2 430.83 for type I, 51.86/101.35/141.04 for type II, and 338.25/540.45/760.52 for type III antibody; the GMIs were 209.54/458.39/454.71 for type I, 7.89/18.10/34.81 for type II, and 116.88/260.05/192.83 for type III antibody among the infants receiving low/moderate/high dose sIPV vaccination and with the antibody titer of equal to or greater than 1 : 8 but less than 1 : 32 before the vaccination; while, the GMIs were 25.35/34.16/90.48 for type I, 1.05/6.17/4.26 for type II, and 11.39/20.97/42.22 for type III antibody among the infants receiving low/moderate/high dose sIPV vaccination and with the antibody titer of greater than 1 : 32 before the vaccination, respectively.
      Conclusion  The immunogenicity of sIPV is generally good and maternal anti-poliovirus antibodies could alleviate the immunogenicity of sIPV at some extent among two-month old infants.

     

/

返回文章
返回